Nuvation Bio Inc.
Expected move
InputsNext report
Last report
Largest filed tie
—
13F top-10 QoQ
Top fund weight
Last report2 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−4.08%
vs ±19.6% implied · ×0.21
shaded = implied · ▲▼ = realized
Nuvation Bio has 1 disclosed supplier and 3 disclosed customers in SEC filings.
SentenceIn December 2018, AnHeart Therapeutics Inc. ("AHT"), a wholly owned subsidiary of AnHeart, entered into a license agreement with Daiichi Sankyo Company, Limited ("Daiichi Sankyo"), pursuant to which Daiichi Sankyo granted to AHT exclusive worldwide rights to develop and commercialize taletrectinib (the "Taletrectinib In-License Agreement").
NUVB 10-Kaccession 0001193125-26-085584
SentenceIn January 2026, we announced a partnership with Eisai Co., Ltd. ("Eisai") to commercialize taletrectinib in Europe and other territories outside the U.S., China and Japan.
NUVB 10-Kaccession 0001193125-26-085584
SentenceTaletrectinib is being commercialized in Japan by our partner Nippon Kayaku Co., Ltd ("NK") under the brand name IBTROZI and in China by our partner Innovent Biologics (Suzhou) Co. Ltd. ("Innovent") under the brand name DOVBLERON®.
NUVB 10-Kaccession 0001193125-26-085584
SentenceTaletrectinib is being commercialized in Japan by our partner Nippon Kayaku Co., Ltd ("NK") under the brand name IBTROZI and in China by our partner Innovent Biologics (Suzhou) Co. Ltd. ("Innovent") under the brand name DOVBLERON®.
NUVB 10-Kaccession 0001193125-26-085584
Nuvation Bio Inc.
4.76
Expected move
Inputs8Q avg ±9.4%·×1.53·rich
straddle ±16.5%
spot 4.76exp Nov 20ATM strike 5ATM straddle 0.93IV 97%